XBiotech (XBiotech) Interest Expense : $0.00 Mil (TTM As of Mar. 2024)

View and export this data going back to 2015. Start your Free Trial

What is XBiotech Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. XBiotech's interest expense for the three months ended in Mar. 2024 was $ 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was $0.00 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. XBiotech's Operating Income for the three months ended in Mar. 2024 was $ -10.85 Mil. XBiotech's Interest Expense for the three months ended in Mar. 2024 was $ 0.00 Mil. XBiotech has no long-term debt ⁽¹⁾. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

(1) Note: An indication of "no long-term debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

XBiotech Interest Expense Historical Data

The historical data trend for XBiotech's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

XBiotech Interest Expense Chart

XBiotech Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

XBiotech Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Interest Expense	Get a 7-Day Free Trial															-	-	-	-	-

XBiotech Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

XBiotech (NAS:XBIT) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

XBiotech's Interest Expense for the three months ended in Mar. 2024 was $0.00 Mil. Its Operating Income for the three months ended in Mar. 2024 was $-10.85 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2024 was $0.00 Mil.

XBiotech's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

XBiotech had no long-term debt ⁽¹⁾.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. XBiotech Inc has enough cash to cover all of its debt. Its financial situation is stable.

XBiotech (XBiotech) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XBiotech Inc (NAS:XBIT) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

4XB:Germany 4XB:Germany

Address

5217 Winnebago Lane, Austin, TX, USA, 78744

Website

http://www.xbiotech.com

XBiotech Inc is a United States based clinical-stage biopharmaceutical company. It is engaged in discovering and developing True Human (antibody technology) monoclonal antibodies for treating a variety of diseases. The company focuses on developing Anti-IL-1 a therapeutic antibody as a treatment for cancer. Geographically, all of its operations are in the United States.

Executives

Angela Hu	officer: Principle Financial Officer	5217 WINNEBAGO LN, AUSTIN TX 78744
John Simard	director, 10 percent owner	8201 E RIVERSIDE DRIVE, BLDG 4, STE 100, AUSTIN TX 78744
Bay Street Financial S.a.	10 percent owner	MEIERHOFSTRASSE 5, LIECHTENSTEIN N2 9490 VADUZ
W Thorpe Mckenzie	director, 10 percent owner	735 BROAD ST, STE 1105, CHATTANOOGA TN 37402
Sushma Shivaswamy	officer: VP of R&D	8201 E RIVERSIDE DRIVE, BLDG 4, STE 100, AUSTIN TX 78744
Queena Han	officer: VP of Fin & HR, Secretary	8201 E RIVERSIDE DRIVE, BLDG 4 STE 100, AUSTIN TX 78744
Thomas Gut	10 percent owner	CO LINDENBERG FAMILY OFFICE LTD, LATERNENGASSE 5, ZURICH V8 8001
Peter Libby	director	109 LARCH ROAD, CAMBRIDGE MA 02138
Fondation Rennes	10 percent owner	RATIKONSTRASSE 13, VADUZ, PRINCIPALITY OF LIECHTENSTEIN N2 FL-9490
Donald H. Macadam	director	56 KELLY DRIVE, PORT DOVER A6 N0A 1N5
Jan-paul Waldin	director	77 KING STREET WEST, SUITE 3000, TORONTO A6 M5K 1G8
Benjamin Guzman	officer: Sr.VP Corp. Strategy & Finance	8201 E RIVERSIDE DR BLDG. 4 STE 100, AUSTIN TX 78744
Trey Benson	officer: VP of Commercial Development	8201 E. RIVERSIDE DR., BUILDING 4, SUITE 100, AUSTIN TX 78744
Kalidip Choudhury	officer: VP of Business Development	8201 E. RIVERSIDE DRIVE, BUILDING 4, SUITE 100, AUSTIN TX 78744
Dawn Mccollough	officer: VP Clinical Operations	115 SANDRA MURAIDA WAY, #838, AUSTIN TX 78703